Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16
| Autor: | Dariusz W Kowalczyk, Anthony P Wlazlo, Hildegund C.J. Ertl, Sara Shane |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Sexually transmitted disease
L1 viruses Immunization Secondary Priming (immunology) Antibodies Viral Injections Intramuscular Virus Cell Line law.invention Epitopes Mice law Vaccines DNA Animals Humans Papillomavirus Vaccines Antigens Viral Papillomaviridae Administration Intranasal Vaccines Synthetic General Veterinary General Immunology and Microbiology biology Papillomavirus Infections Public Health Environmental and Occupational Health Viral Vaccines Oncogene Proteins Viral Virology Mice Inbred C57BL Microscopy Electron Tumor Virus Infections Regimen Infectious Diseases COS Cells Immunology biology.protein Recombinant DNA Molecular Medicine Capsid Proteins Female Nasal administration Antibody |
| Zdroj: | Vaccine. 19:3583-3590 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/s0264-410x(01)00070-6 |
| Popis: | Protection to sexually transmitted infections with oncogenic human papillomaviruses (HPV) such as type 16 is thought to be provided by neutralizing antibodies directed to the major outer capsid protein, the L1 protein. A DNA vaccine and an E1-deleted adenoviral recombinant human strain 5, both expressing the L1 protein of HPV-16, were developed and shown to express L1 protein able to assemble into virus-like particles (VLPs). The vaccines used in a prime-boost regimen, with the DNA given intramuscularly (i.m.) for priming, followed by an intranasal (i.n.) booster immunization with the viral recombinant, induced antibodies to L1 in sera and in vaginal secretions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect